Av Vania Morelli
Forsker ved TREC
Anticoagulants, commonly referred to as blood thinners, are drugs used to prevent the
formation of blood clots in the blood vessels or in the heart. A new generation of drugs, the so-called direct oral anticoagulants (DOACs), has emerged as an interesting alternative to warfarin, a well-known anticoagulant by clinicians, for oral anticoagulation. A new study searched for a therapeutic strategy to manage life-threatening bleeding in patients who use DOACs.
By Søren Beck Jensen, postdoc TREC
An anthropologist friend of mine once told me about a field study where he attempted to decipher the religious thoughts of an Inuit tribe. The Elder who had always lived on the edge of the world was very reluctant to give any answers about this, to him, taboo topic but finally gave one piece of information: We do not believe. We fear. Continue reading
By Robin Liang, PhD in TREC
The ideal duration of anticoagulation following an unprovoked pulmonary embolism is controversial.
Studies have shown that after anticoagulant therapy is stopped after 3 or 6 months following an unprovoked venous thromboembolism (VTE), patients have a much higher risk than those VTE events provoked by known risk factors. Previous studies have shown that extended therapy reduces the risk in these high-risk patients, but whether this benefit is maintained in the long-term has not yet been investigated. Continue reading
